用氨基羟丙基二膦酸盐治疗甲状腺毒症中的高钙血症。
Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.
作者信息
Tan T T, Alzaid A A, Sutcliffe N, Gardner M D, Thomson J A, Boyle I T
机构信息
University Department of Medicine, Royal Infirmary, Glasgow, UK.
出版信息
Postgrad Med J. 1988 Mar;64(749):224-7. doi: 10.1136/pgmj.64.749.224.
Abstract
Two patients had symptomatic hypercalcaemia accompanying thyrotoxicosis, despite initial treatment with volume repletion, beta blockade and antithyroid drugs. They were further managed with intravenous infusions of aminohydroxypropylidene diphosphonate resulting in rapid normalization of the serum calcium, with relief of symptoms. Aminohydroxypropylidene diphosphonate effectively suppressed the increased bone resorption of thyrotoxicosis without any undesirable adverse effects.
摘要
两名患者在伴有甲状腺毒症的情况下出现了症状性高钙血症，尽管最初采用了补液、β受体阻滞剂和抗甲状腺药物治疗。他们进一步接受了静脉输注氨羟丙基二膦酸盐治疗，血清钙迅速恢复正常，症状得到缓解。氨羟丙基二膦酸盐有效地抑制了甲状腺毒症时增加的骨吸收，且无任何不良副作用。
相似文献
1
Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.
Postgrad Med J. 1988 Mar;64(749):224-7. doi: 10.1136/pgmj.64.749.224.
2
Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
Br Med J (Clin Res Ed). 1986 Jun 14;292(6535):1549-50. doi: 10.1136/bmj.292.6535.1549.
3
Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.
Br Med J (Clin Res Ed). 1987 Feb 21;294(6570):467-9. doi: 10.1136/bmj.294.6570.467.
4
Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia.
Lancet. 1986 Jan 18;1(8473):165-6. doi: 10.1016/s0140-6736(86)92309-3.
5
Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Lancet. 1985 Oct 26;2(8461):907-10. doi: 10.1016/s0140-6736(85)90848-7.
6
Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.
Postgrad Med J. 1989 Apr;65(762):244-6. doi: 10.1136/pgmj.65.762.244.
7
Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
Bone Miner. 1990 May;9(2):121-8. doi: 10.1016/0169-6009(90)90078-t.
8
Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Br Med J (Clin Res Ed). 1988 Mar 19;296(6625):811-4. doi: 10.1136/bmj.296.6625.811.
9
Abdominal symptoms, hypercalcaemia and apathetic hyperthyroidism: treatment with pamidronate.
Br J Clin Pract. 1994 May-Jun;48(3):163-4.
10
Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism.
Aust N Z J Med. 1987 Feb;17(1):58-9. doi: 10.1111/j.1445-5994.1987.tb05052.x.
引用本文的文献
1
Causes of anorexia in untreated hyperthyroidism: a prospective study.
Postgrad Med J. 2000 May;76(895):292-4. doi: 10.1136/pmj.76.895.292.
2
Clinical experience with pamidronate in the treatment of Paget's disease of bone.
Ann Rheum Dis. 1991 Dec;50(12):930-3. doi: 10.1136/ard.50.12.930.
3
Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Drugs. 1991 Feb;41(2):289-318. doi: 10.2165/00003495-199141020-00009.
4
Medical management of hypercalcaemia.
Br J Clin Pharmacol. 1992 Jul;34(1):11-20. doi: 10.1111/j.1365-2125.1992.tb04101.x.
本文引用的文献
1
The effect of thyroid disease on calcium metabolism in man.
J Clin Invest. 1956 Aug;35(8):874-87. doi: 10.1172/JCI103340.
2
Predictive value of derived calcium figures based on the measurement of ionised calcium.
Ann Clin Biochem. 1981 Mar;18 (Pt 2):106-9. doi: 10.1177/000456328101800210.
3
Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.
Br Med J (Clin Res Ed). 1984 May 12;288(6428):1405-8. doi: 10.1136/bmj.288.6428.1405.
4
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia.
Lancet. 1983 Jul 30;2(8344):239-43. doi: 10.1016/s0140-6736(83)90231-3.
5
Symptomatic hypercalcaemia in thyrotoxicosis.
Br Med J. 1970 Jun 20;2(5711):701-3. doi: 10.1136/bmj.2.5711.701.
6
Thyrotoxic hypercalcaemia treated with porcine calcitonin.
Lancet. 1969 Jun 7;1(7606):1128-30. doi: 10.1016/s0140-6736(69)91646-8.
7
Hypercalcemia of thyrotoxicosis.
Ann Intern Med. 1966 Sep;65(3):429-42. doi: 10.7326/0003-4819-65-3-429.
8
Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.
Br Med J (Clin Res Ed). 1987 Feb 21;294(6570):467-9. doi: 10.1136/bmj.294.6570.467.
9
Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
Br Med J (Clin Res Ed). 1986 Jun 14;292(6535):1549-50. doi: 10.1136/bmj.292.6535.1549.
10
Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Lancet. 1985 Oct 26;2(8461):907-10. doi: 10.1016/s0140-6736(85)90848-7.
Zotero 插件